Drugs / Synacthen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT02127840 | Mar 2011 → Dec 2014 | primary aldosteronism | Charles University, Czech Republic | Unknown | No outcome recorded |
| Phase 4 | NCT00851942 | Sep 2008 → Jul 2012 | adrenocortical insufficiency, hypopituitarism | Cardiff University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT02818660 Background | May 2016 → Dec 2017 | adrenocortical insufficiency | Haukeland University Hospital | Completed | No outcome recorded |
| — | NCT00552487 Background | Oct 2005 → Jul 2006 | Hashimoto thyroiditis, secondary adrenal insufficiency | University of Wuerzburg | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synacthen | “The patient get Synacthen to stimulate the adrenals to produce cortisol” NCT02818660 ↗ |
| Known as | Tetracosactrin | “Synacthen (Tetracosactrin)” NCT00851942 ↗ |
| Route | Intravenous | “1 µg synacthen in the vein” NCT00552487 ↗ |